(−)-epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the mek/erk signaling pathway in human osteosarcoma cells

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 34, Issue 1, 2015, Pages 85-93

  Tang, Guoqing ^a   Zhang, Zhengshi ^a   Qian, Hongbin ^a   Chen, Ji ^a   Wang, Yong ^a   Chen, Xiang ^a   Chen, Bin ^a   Chen, Yong ^a  

^a Kunshan Hospital of Traditional Chinese Medicine   (China)

Author keywords

EGCG; ERK; Invasion; MEK; Migration; Osteosarcoma cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIGALLOCATECHIN GALLATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; CATECHIN;

ARTICLE; CANCER INHIBITION; CELL ADHESION ASSAY; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CYTOTOXICITY ASSAY; DRUG EFFECT; HUMAN; HUMAN CELL; METASTASIS; MTT ASSAY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL ADHESION; CELL MOTION; DRUG EFFECTS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

BONE NEOPLASMS; CATECHIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; OSTEOSARCOMA;

EID: 84924367153     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2015011925     Document Type: Article

References (23)

1. Seker MM, Seker A, Aksoy S, Ozdemir N, Uncu D, Zengin N. Clinicopathologic features and prognosis of osteosarcoma in Turkish adults. Asian Pac J Cancer Prev. 2014;5:3537-40.
2. Green JT, Mills AM. Osteogenic tumors of bone. Semin Diagn Pathol. 2014;31:21-9.
3. Wiromrat P, Jetsrisuparb A, Komvilaisak P, Sirichativapee W, Kamsa-Ard S, Wiangnon S. Incidence and survival rates among pediatric osteogenic sarcoma cases in Khon Kaen, Thailand, 1985-2010. Asian Pac J Cancer Prev. 2012;13:4281-4.
4. Dürr HR, Tunn PU, Bakhshai Y. Surveillance in patients with bone sarcomas. When, how, and for how long? Unfallchirurg. 2014; 177:523-7.
5. Bi W, Wang W, Han G, Jia J, Xu M. Osteosarcoma around the knee treated with neoadjuvant chemotherapy and a custom-designed prosthesis. Orthopedics. 2013;36:e444-50.
6. Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, Comanone A, Bertulli R, Bisogno G, Palmerini E, Alberghini M, Parafioriti A, Linari A, Picci P, Bacci G. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;10:2112-8.
7. Knight T, Irving JA. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol. 2014;4:1-12.
8. Saito H. Regulation of cross-talk in yeast MAPK signaling pathways. Curr Opin Microbiol. 2010;13:677-83.
9. Zheng J, Du W, Song LJ, Zhang R, Sun LG, Chen FG, Wei XT. Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ ERK pathway. World J Surg Oncol. 2014;15:207-12.
10. Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z, Chen X, Qin N, Zhang X. Targeting cadherin-17 inactivates Ras/ Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer. PLoS One. 2014;9:e85296.
11. Webb CP, Van AL, Wigler MH, Woude GF. Signaling pathways in ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA. 1998;95:8773-8.
12. Niu J, Mo Q, Wang H, Li M, Cui J, Lin Z, Lin Z. Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells. Biochem Biophys Res Commun. 2012;422:80-4.
13. Harakeh S, Diab-Assaf M, Azar R, Hassan HM, Tayeb S, Abou-El-Ardat K, Damanhouri GA, Qadri I, Abuzenadah A, Chaudhary A, Kumosani T, Niedzwiecki A, Rath M, Yacoub H, Azhar E, Barbour E. Epigallocatechin-3- gallate inhibits tax-dependent activation of nuclear factor kappa B and of matrix metalloproteinase 9 in human T-cell lymphotropic virus-1 positive leukemia cells. Asian Pac J Cancer Prev. 2014;15:1219-25.
14. Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011;102:317-23.
15. Tang GQ, Yan TQ, Guo W, Ren TT, Peng CL, Zhao H, Lu XC, Zhao FL, Han X. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol. 2010;136: 1179-85.
16. Ji SJ, Han DH, Kim JH. Inhibition of proliferation and induction of apoptosis by EGCG in human osteogenic sarcoma (HOS) cells. Arch Pharm Res. 2006;29:363-8.
17. Hawkins DS, Arndt CA. Manipulation therapy prior to diagnosis induced primary osteosarcoma metastasis-from clinical to basic research. PLoS One. 2014;9:e96571.
18. Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, Bruland OS. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol. 2014;24:1-9.
19. Wang F, Chang Z, Fan Q, Wang L. Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2. Mol Med Rep. 2014;9:1085-9.
20. Suzuki Y, Isemura M. Binding interaction between (-)-epigallocatechin gallate causes impaired spreading of cancer cells on fibrinogen. Biomed Res. 2013;34:301-8.
21. Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013;13:632-7.
22. Zhang Y, Owusu L, Duan W, Jiang T, Zang S, Ahmed A, Xin Y. Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells. Int J Mol Med. 2013;32:959-64.
23. Wang Y, Zhu Y, Zhang L, Tian W, Hua S, Zhao J, Zhang H, Xue F. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 2012;322:223-31.